While I am not sure what Invion is going to do my guess is that they will either sell or partner their lupus asset and use the proceeds to fund their respiratory franchise which IMO has the biggest potential. If they go down the CR path again I think there will be some unhappy shareholders, including me. What I find interesting is that they are proceeding with the manufacture of their inhaled nadolol and inhaled zafirlukast for the phase 1 trials, so it reflects their confidence in the products.
Biotech Business Strategies, page-5
Add IVX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.001(10.0%) |
Mkt cap ! $35.33M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.6¢ | 0.5¢ | $1.436K | 272.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 3782556 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 14782697 | 12 |
View Market Depth
| Last trade - 14.56pm 23/05/2024 (20 minute delay) ? |
| IVX (ASX) Chart |